Inflammation:IL-33因子通过诱导MMP-9和TIMP-1水平的失衡,促进肺纤维化

2018-02-11 MedSci MedSci原创

IL-33可以通过诱导MMP-9和TIMP-1之间的失衡来促进ECM的沉积,促进肺纤维化的过程。 原始出处

IL-33在炎性疾病中发挥了重要作用,在病变组织中的表达水平较高。先前的研究表明,IL-33/ST2L信号转导通路参与了A549细胞的上皮-间质转化(EMT)。细胞因子IL-1beta可通过激活NF-kB来增加MMPs的表达。MMP-9的过度或不恰当的表达可能会随机和非选择性地破坏细胞外基质。TIMP-1 (MMP-9的组织抑制剂)通过抑制MMP-9的激活,影响ECM水平。因此,IL-33可以通过调节MMP-9和TIMP-1的表达参与肺纤维化的过程。

为探讨IL-33在肺纤维化中的作用机制,体外分析了人胚胎肺成纤维细胞的增殖和相关信号分子的表达。培养HELF细胞,并在不同时间点(24、48、72 h)和不同浓度,采用rhIL-33刺激HELF细胞。采用RT-PCR方法对受体ST2L的表达进行分析,并通过MTT法检测HELF的增殖率。采用Western blotting法检测胶原蛋白IV、MMP-9、TIMP-1、关键信号传感器TRAF-6和NF-kappaB水平的表达。

RhIL-33可以促进HELF细胞的增殖,RhIL-33浓度为10 ng/ml时,72 h时HELF细胞的增殖最为显著(P < 0.05)。因此,本实验选择10 ng/ml作为后续实验的刺激浓度。胶原蛋白IV、MMP-9、TIMP-1、TRAF-6和NF-kappaB的表达增加,在不同时间点(0、6、12、24、48、72 h)蛋白水平有所降低(P < 0.05)。IL-33参与了肺纤维化早期炎症反应中促纤维化细胞因子的生成和间充质物质的形成。IL-33可以通过诱导MMP-9和TIMP-1之间的失衡来促进ECM的沉积,促进肺纤维化的过程。

原始出处

Wu L, Luo Z, Zheng J, et al. IL-33 Can Promote the Process of Pulmonary Fibrosis by Inducing the Imbalance Between MMP-9 and TIMP-1.Inflammation, 2018, Feb 7. doi: 10.1007/s10753-018-0742-6.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2057617, encodeId=6b61205e617f2, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Mar 29 22:49:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978113, encodeId=ed5119e8113d1, content=<a href='/topic/show?id=327b1203115' target=_blank style='color:#2F92EE;'>#MMP-9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12031, encryptionId=327b1203115, topicName=MMP-9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 11 18:49:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454829, encodeId=5f19145482938, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Tue Feb 13 11:49:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466239, encodeId=5b571466239f6, content=<a href='/topic/show?id=9063966407' target=_blank style='color:#2F92EE;'>#IL-33#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9664, encryptionId=9063966407, topicName=IL-33)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42dd6785219, createdName=宋威, createdTime=Tue Feb 13 11:49:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545554, encodeId=fcd2154555482, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Tue Feb 13 11:49:00 CST 2018, time=2018-02-13, status=1, ipAttribution=)]
    2018-03-29 lxg951
  2. [GetPortalCommentsPageByObjectIdResponse(id=2057617, encodeId=6b61205e617f2, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Mar 29 22:49:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978113, encodeId=ed5119e8113d1, content=<a href='/topic/show?id=327b1203115' target=_blank style='color:#2F92EE;'>#MMP-9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12031, encryptionId=327b1203115, topicName=MMP-9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 11 18:49:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454829, encodeId=5f19145482938, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Tue Feb 13 11:49:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466239, encodeId=5b571466239f6, content=<a href='/topic/show?id=9063966407' target=_blank style='color:#2F92EE;'>#IL-33#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9664, encryptionId=9063966407, topicName=IL-33)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42dd6785219, createdName=宋威, createdTime=Tue Feb 13 11:49:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545554, encodeId=fcd2154555482, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Tue Feb 13 11:49:00 CST 2018, time=2018-02-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2057617, encodeId=6b61205e617f2, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Mar 29 22:49:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978113, encodeId=ed5119e8113d1, content=<a href='/topic/show?id=327b1203115' target=_blank style='color:#2F92EE;'>#MMP-9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12031, encryptionId=327b1203115, topicName=MMP-9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 11 18:49:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454829, encodeId=5f19145482938, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Tue Feb 13 11:49:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466239, encodeId=5b571466239f6, content=<a href='/topic/show?id=9063966407' target=_blank style='color:#2F92EE;'>#IL-33#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9664, encryptionId=9063966407, topicName=IL-33)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42dd6785219, createdName=宋威, createdTime=Tue Feb 13 11:49:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545554, encodeId=fcd2154555482, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Tue Feb 13 11:49:00 CST 2018, time=2018-02-13, status=1, ipAttribution=)]
    2018-02-13 xiaoyeshuang
  4. [GetPortalCommentsPageByObjectIdResponse(id=2057617, encodeId=6b61205e617f2, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Mar 29 22:49:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978113, encodeId=ed5119e8113d1, content=<a href='/topic/show?id=327b1203115' target=_blank style='color:#2F92EE;'>#MMP-9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12031, encryptionId=327b1203115, topicName=MMP-9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 11 18:49:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454829, encodeId=5f19145482938, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Tue Feb 13 11:49:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466239, encodeId=5b571466239f6, content=<a href='/topic/show?id=9063966407' target=_blank style='color:#2F92EE;'>#IL-33#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9664, encryptionId=9063966407, topicName=IL-33)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42dd6785219, createdName=宋威, createdTime=Tue Feb 13 11:49:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545554, encodeId=fcd2154555482, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Tue Feb 13 11:49:00 CST 2018, time=2018-02-13, status=1, ipAttribution=)]
    2018-02-13 宋威
  5. [GetPortalCommentsPageByObjectIdResponse(id=2057617, encodeId=6b61205e617f2, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Mar 29 22:49:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978113, encodeId=ed5119e8113d1, content=<a href='/topic/show?id=327b1203115' target=_blank style='color:#2F92EE;'>#MMP-9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12031, encryptionId=327b1203115, topicName=MMP-9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 11 18:49:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454829, encodeId=5f19145482938, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Tue Feb 13 11:49:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466239, encodeId=5b571466239f6, content=<a href='/topic/show?id=9063966407' target=_blank style='color:#2F92EE;'>#IL-33#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9664, encryptionId=9063966407, topicName=IL-33)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42dd6785219, createdName=宋威, createdTime=Tue Feb 13 11:49:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545554, encodeId=fcd2154555482, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Tue Feb 13 11:49:00 CST 2018, time=2018-02-13, status=1, ipAttribution=)]

相关资讯

JASN:防止肾小球硬化新靶点?——先天淋巴样细胞

先天淋巴样细胞(ILCs)在针对不同形式的传染性和非传染性疾病的免疫反应中发挥了重要作用。特别是,IL-5和IL-13产生的2型ILCs(ILC2s)参与了在损伤后恢复组织的完整性的修复机制。但是在人类肾中的ILCs却尚未报道

Sci Signal:FAK导致肿瘤免疫逃逸的机制

肿瘤非常善于逃避免疫系统的监察和抑制免疫系统活性,而粘着斑激酶 (focal adhesion kinase, FAK) 被认为在媒介肿瘤免疫逃逸中起到重要作用。

Nature子刊:谁给癌细胞穿上了“隐形衣”?

导语:哈利波特的隐身斗篷是很多人梦寐以求的东西。这件“神器”帮助主人躲过了很多危险。今天,小编要介绍的是癌细胞的“隐身衣”,它也帮助“主人”巧妙的躲过免疫系统的监视,让主人威武壮大。那么,癌细胞的“隐身衣”是什么做的呢?9月13日,发表在Scientific Reports上的一项研究中,英属哥伦比亚大学(University of British Columbia,UBC)的科学家们发现了癌细胞

GSK牵手强生共同开发哮喘药物---IL-33单抗

近年来,随着污染以及各方面因素的变化,哮喘症患者群体越来越大,催生出了一个巨大的药物市场。英国制药巨头GSK公司最近宣布和强生旗下的杨森制药达成了一项总价值达2亿3千万美元的协议,获得后者一项用于治疗重度哮喘症药物CNTO 7160全球销售权。按照协议,公司将在杨森公司完成该药物的临床I期研究后接手后续的研发工作。这种药物是一种靶向IL-33的单克隆抗体药物。该药物被认为能够通过阻断IL-33与S

PNAS:中科院院士叶玉如发现新蛋白IL-33可逆转老年痴呆

由香港科技大学和英国格拉斯哥大学的科学家们领导的一项研究发现,一种叫做IL-33的蛋白可以逆转小鼠阿尔茨海默病样的病状和认知功能下降。这项研究发表在4月18日的《美国国家科学院院刊》(PNAS)上。 中科院院士、香港科技大学叶玉如(Nancy Y Ip)教授,及格拉斯哥大学感染、免疫与炎症研究所的Eddy Liew教授是这项研究的共同领导者。叶玉如教授主要研究神经营养因子与神

PNAS:清华大学王新泉等人解析IL-33与受体作用的结构机制

IL-33是IL-1家族的一个重要成员,在宿主防御及疾病的先天和适应性免疫反应中发挥着多效活性。IL-33通过它的配体结合主要受体 ST2 和IL-1受体辅助蛋白(IL-1RAcP)来发送信号,这两种受体均为IL-1受体家族成员。 为了阐明IL-33与它的受体之间的相互作用,来自清华大学生命科学学院等机构的研究人员确定了分辨率为 3.27 的 IL-33 与 ST